| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2025-11-05. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Bio-Techne to report an earnings per share (EPS) of $0.40.
Investors in Bio-Techne are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
In the previous earnings release, the company beat EPS by $0.05, leading to a 0.56% increase in the share price the following trading session.
Here's a look at Bio-Techne's past performance and the resulting price change:
| Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| EPS Estimate | 0.48 | 0.51 | 0.38 | 0.38 |
| EPS Actual | 0.53 | 0.56 | 0.42 | 0.42 |
| Price Change % | 1.00 | 2.00 | 0.00 | -3.00 |
Shares of Bio-Techne were trading at $61.26 as of November 03. Over the last 52-week period, shares are down 17.88%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Bio-Techne.
A total of 5 analyst ratings have been received for Bio-Techne, with the consensus rating being Buy. The average one-year price target stands at $69.2, suggesting a potential 12.96% upside.
In this comparison, we explore the analyst ratings and average 1-year price targets of Charles River, Qiagen and Repligen, three prominent industry players, offering insights into their relative performance expectations and market positioning.
The peer analysis summary presents essential metrics for Charles River, Qiagen and Repligen, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Bio-Techne | Buy | 3.55% | $198.81M | -0.90% |
| Charles River | Neutral | 0.59% | $357.07M | 1.60% |
| Qiagen | Neutral | 7.49% | $334.29M | 2.78% |
| Repligen | Outperform | 3.53% | $91.14M | 1.19% |
Key Takeaway:
Bio-Techne ranks first in revenue growth among its peers. It has the lowest gross profit and return on equity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Bio-Techne displayed positive results in 3 months. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately 3.55%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Bio-Techne's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.58%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Bio-Techne's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.9%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Bio-Techne's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.68%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.23.
To track all earnings releases for Bio-Techne visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TECH
